论文部分内容阅读
目的探讨长春瑞滨联合顺铂治疗经紫杉醇+蒽环类联合化疗失败的局部晚期乳腺癌和复发转移乳腺癌的疗效及安全性。方法 10例采用紫杉醇+蒽环类化疗耐药的局部晚期乳腺癌和31例手术后紫杉醇+蒽环类辅助治疗的转移性乳腺癌患者,应用长春瑞滨(25mg/m2,第1,8天,静脉滴注)、顺铂(30mg/m2,第1～3天,静脉滴注)化疗,对其疗效及不良反应进行分析。结果全组患者完全缓解6例(14.6%),部分缓解17例(41.5%)。不良反应以骨髓抑制、消化道反应常见。结论长春瑞滨联合顺铂方案对蒽环类和(或)紫杉醇耐药的乳腺癌疗效较好,值得临床进一步研究。
Objective To investigate the efficacy and safety of vinorelbine plus cisplatin in the treatment of locally advanced breast cancer and recurrent metastatic breast cancer who have failed paclitaxel + anthracycline chemotherapy. Methods Ten patients with metastatic breast cancer who were treated with paclitaxel + anthracycline chemotherapy and 31 patients with postoperative paclitaxel + anthracycline adjuvant therapy were treated with vinorelbine (25 mg / m 2, days 1 and 8 , Intravenous infusion), cisplatin (30mg / m2, 1 to 3 days, intravenous infusion) chemotherapy, its efficacy and adverse reactions were analyzed. Results All the patients in complete remission in 6 cases (14.6%), partial remission in 17 cases (41.5%). Adverse reactions to bone marrow suppression, gastrointestinal reactions common. Conclusion The combination of vinorelbine and cisplatin is effective in anthracycline-resistant and / or paclitaxel-resistant breast cancer and deserves further clinical study.